Epitalon

The tetrapeptide Ala-Glu-Asp-Gly (AEDG). The best-documented compound in the Khavinson range — and the one whose most impressive human data were generated with a different substance entirely.

Educational only
This site is for informational purposes and is not medical advice. See the medical disclaimer and editorial policy.
Educational only

This page is for general educational and informational purposes only. It is not medical advice and does not replace professional medical judgment. Always consult a qualified clinician before starting, stopping, or changing any medication or protocol.

Overview

Epitalon, also spelled Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly, indexed by the US National Library of Medicine as alanyl-glutamyl-aspartyl-glycine and coded AE-0. With roughly 140 PubMed records it is comfortably the most-cited synthetic peptide in this family.

The substitution most write-ups miss

Epitalon (AEDG) is a defined synthetic tetrapeptide. Epithalamin is a peptide extract of animal pineal gland. The long human follow-up data usually cited for "Epitalon" were collected with Epithalamin.

Mechanism of action

The mechanism that made Epitalon famous is telomerase induction. In telomerase-negative human fetal fibroblasts it was reported to switch on the catalytic subunit of telomerase, produce measurable enzyme activity and lengthen telomeres ( Khavinson, Bondarev & Butyugov, Bull Exp Biol Med 2003;135(6):590-2). The marketing that quotes this rarely notes that re-activating telomerase in somatic cells is also a hallmark of cancer biology, which is why industry has spent more effort inhibiting the enzyme than switching it on.

Indications and use context

There is no approved indication for AEDG anywhere. The dataset people reach for is a 15-year follow-up in which 39 coronary patients received six courses of a peptide geroprotector over three years against 40 controls on basic therapy, reporting decelerated cardiovascular ageing and lower mortality ( Korkushko, Khavinson et al., Bull Exp Biol Med 2011). The agent there was epithalamin — and that paper's own title and abstract disagree on whether the extract came from the pituitary or the pineal gland. A separate Russian report gave both preparations to old monkeys and elderly people and described restored night-time melatonin, without stating numbers ( Korkushko et al., Adv Gerontol 2007).

Safety and side effects

Long-term human safety data do not exist. The animal signal is mixed: in Swiss-derived SHR mice, total spontaneous tumour incidence was unchanged between groups, though leukaemia occurred sixfold less often in treated animals ( Anisimov et al., Biogerontology 2003). A compound whose proposed mechanism is telomerase activation, and whose only tumour data come from its own developers, has not been cleared of oncological risk.

Pharmacology and dosing considerations

What the actual protocols were

In the SHR mouse study the dose was 1.0 µg per mouse — roughly 30–40 µg/kg — subcutaneously on five consecutive days each month. That is not a human dose for AEDG; it appears here so readers can see what the underlying protocol was.

The milligram-per-day figures circulating in bioregulator marketing are orders of magnitude above those microgram animal doses, and we could not trace them to a peer-reviewed source. Human pharmacokinetics for AEDG have never been published.

Formulations and combinations

A lyophilised powder, usually sold with Pinealon in "longevity" bundles though nothing has been published on the pair. In laboratory panels AEDG is tested beside AED (Cartalax), from which it differs only by a terminal glycine.

Research and evidence snapshot

Evidence tier: minimal

The largest file in this family, and still no randomised controlled trial of the synthetic peptide in humans.

The 2003 mouse study is the most quantitative result available: 54 animals per group, no change in mean lifespan, maximum lifespan up 12.3%, lifespan of the final 10% of survivors up 13.3%. Note the shape of that — the average mouse did not live longer. Beyond it the AEDG literature is cell-culture work on telomerase and chromatin, published overwhelmingly in Bulletin of Experimental Biology and Medicine and Advances in Gerontology with Khavinson or Anisimov on most author lists. Volume is not the problem; independence is.

References

  1. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsPubMed
  2. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activityPubMed
  3. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR micePubMed

Frequently asked questions

Is there human evidence that Epitalon slows ageing? The 15-year cardiology follow-up so often quoted used epithalamin, the animal extract. AEDG itself appears only in a 2007 Russian melatonin report with no stated sample size. No randomised controlled trial of AEDG has been published or registered.

Does it lengthen telomeres in people, and is that a good thing? Lengthening was observed in cultured fetal fibroblasts in 2003; whether it happens in a living person has not been measured. Persistent telomerase activity is also one way tumour cells escape replicative limits, so the claim carries a concern single-laboratory rodent data cannot resolve.

How does Epitalon differ from Pinealon? Epitalon is Ala-Glu-Asp-Gly, studied for telomerase and lifespan; Pinealon is Glu-Asp-Arg, studied for reactive oxygen species in neural cells.

Is it approved anywhere? No. It has no marketing authorisation from the FDA, EMA or MHRA and is distributed as a research chemical.

Compounds related to Epitalon

Grouped by catalog family, category and shared research themes. For the wider picture, read the Neuro / nootropic / cosmetic class overview or browse the full peptide catalog.

Key studies

Curated primary literature for Epitalon. Links open the publisher or PubMed record in a new tab.

  1. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsPubMed
  2. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activityPubMed
  3. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR micePubMed

Search the literature

PubMed · ClinicalTrials.gov · Google Scholar

Stay Updated

Get the Standard Protocols.

Join 12,000+ researchers. Receive weekly breakdowns of new compounds, safety data updates, and source verification reports.

No spam. Unsubscribe anytime.